Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/1996
12/17/1996US5585403 Sterilizing agent for preventing coccidiosis in animals
12/17/1996US5585402 Inhibiting tissue damage caused by pathological nitric oxide production by administering nitric oxide synthase inhibitor
12/17/1996US5585401 Method for enhancing outflow of aqueous humor in treatment of glaucoma
12/17/1996US5585400 Administering conjugated linoleic acid
12/17/1996US5585399 Preventing injuries and retaining flexibility of erythrocytes by treatment with solutions of triglycerides of mono- or di-unsaturated fatty acids
12/17/1996US5585398 Topical anesthetic comprising lidocaine, adrenaline, and tetracaine, and its method of use
12/17/1996US5585397 Viricides
12/17/1996US5585396 Side effect reduction
12/17/1996US5585394 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives
12/17/1996US5585391 N,n-disubstituted aminoacetic salt
12/17/1996US5585390 Alpha-amino acid compounds
12/17/1996US5585388 Substituted pyridines useful as modulators of acetylcholine receptors
12/17/1996US5585386 Mixtures for application to skin or scalp
12/17/1996US5585385 Heterocyclic compounds, their production and use as tachykinin reactor antagonists
12/17/1996US5585382 Anticarcinogenic agents
12/17/1996US5585380 Modulation of cellular response to external stimuli
12/17/1996US5585379 Skin disorders
12/17/1996US5585378 Can be administered for the prevention and treatment of cognitive dysfunctions
12/17/1996US5585376 1,5-benzodiazepine derivatives having CCK and/or gastrin antagonistic activity
12/17/1996US5585375 Method for alleviating jet lag
12/17/1996US5585374 Anxiolytic agents, antidepressants, cognition activators
12/17/1996US5585373 3-(7'-oxo-1'-aza-4'-oxabicyclo[3.2.0]-hept-3'-YL)propionic acid derivative as antitumor agent
12/17/1996US5585372 Tricyclic cefem sulphones
12/17/1996US5585371 Treatment of immune system with Δ5-androstenes
12/17/1996US5585370 A female contraceptive regimen using lower dosages of steroids; daily units arranged in alternating estrogen dominant phases and progesterone dominant phases
12/17/1996US5585369 Method of treating low bone turnover osteoporosis with (205) vitamin D compounds
12/17/1996US5585368 Skin disorders
12/17/1996US5585367 Method of treating humans and animals infected with viruses of the retrovirus group
12/17/1996US5585366 Lowering blood cholesterol levels using water soluble cellulose ethers
12/17/1996US5585365 Antiviral polysaccharide
12/17/1996US5585362 Adenovirus vectors for gene therapy
12/17/1996US5585361 Intravenous administration of hyaluronic acid or its salts
12/17/1996US5585358 Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
12/17/1996US5585357 Heteroaryloxymethyl ketones as interleukin-1βconverting enzyme inhibitors
12/17/1996US5585348 Administering antagonists before or during treatment, reduced side effects
12/17/1996US5585347 Measuring prolactin level in blood at spaced intervals during subjects waking and sleeping periods over twenty four hours to create a profile; comparing to control
12/17/1996US5585344 Liver-derived receptors for advanced glycosylation endproducts and uses thereof
12/17/1996US5585111 Transdermal delivery device
12/17/1996US5585109 Cosmetic delivery system for salicylic acid and process for preparation of same
12/17/1996US5585106 Nonspecific defense mechanism; administering phagocytosable particles of a particular size to enhance macrophage oxidizing activity; pretreatment for surgery, prosthetics; anticancer agents; aids
12/17/1996CA2151975A1 Regulex plus 21, anti-cholesterol food supplement
12/17/1996CA2111461C 3-aminopiperidine derivatives and related nitrogen containing heterocycles
12/17/1996CA2059526C Partial agonists of the strychnine insensitive glycine modulatory site of the n-methyl-d-asparate receptor complex as neuropsychopharmacological agents
12/17/1996CA2013809C Agent for the prophylaxis of atopy and methods for preparing and using same
12/16/1996CA2220988A1 Fibroblast growth factor 13
12/14/1996CA2178849A1 N-[(1,4-diazabicyclo[2.2.2]oct-2-yl)methyl]benzamide derivatives, their preparation and their application in therapeutics
12/14/1996CA2178691A1 Oral formulations of s(+)-ibuprofen
12/14/1996CA2178686A1 Oral formulations of s(+)-etodolac
12/12/1996WO1996039541A1 Colon specific gene and protein
12/12/1996WO1996039519A1 Kunitz type plasma kallikrein inhibitors
12/12/1996WO1996039515A1 Human vascular endothelial growth factor 2
12/12/1996WO1996039514A1 Method for prolonging the expression of a gene of interest using soluble ctla4 molecules
12/12/1996WO1996039511A2 A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
12/12/1996WO1996039499A1 TNF-α RIBOZYMES, TNF-α RIBOZYME BINDING PROTEIN AND DEGRADATION RESISTANT mRNA DERIVATIVES LINKED TO TNF-α RIBOZYMES
12/12/1996WO1996039497A1 Transforming growth factor alpha hi
12/12/1996WO1996039496A1 Use of neuro-derived fetal cell lines for transplantation therapy
12/12/1996WO1996039449A1 Hydrophobic heteroatom-containing sequestrant for cholesterol depletion
12/12/1996WO1996039415A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION
12/12/1996WO1996039411A1 Substituted liposaccharides useful in the treatment and prevention of endotoxemia
12/12/1996WO1996039410A1 Disodium alendronate formulations
12/12/1996WO1996039408A1 TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-α]PYRIDINES
12/12/1996WO1996039407A1 Quinolizinone type compounds
12/12/1996WO1996039406A1 NOVEL CRYSTAL FORM OF ANHYDROUS 7-([1α, 5α, 6α]-6-AMINO-3-AZABICYCLO[3.1.0]HEX-3-YL)-6-FLUORO-1-(2,4-DIFLUOROPHENYL)-1,4-DIHYDRO-4-OXO-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID, METHANESULFONIC ACID SALT
12/12/1996WO1996039405A1 Pyridiniminyl-1,2-benzisoxazoles and- benzisothiazoles as antipsychotic agents
12/12/1996WO1996039401A1 Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
12/12/1996WO1996039400A1 Amino-substituted thiadiazoles, pyrimidines, triazines or triazoles useful as ctf receptor antagonists
12/12/1996WO1996039397A1 Benzisoxazole and indazole derivatives as antipsychotic agents
12/12/1996WO1996039396A1 Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
12/12/1996WO1996039391A1 Styryl benzimidazole derivatives as inhibitors of smooth muscle cell proliferation
12/12/1996WO1996039390A1 Benzimidazole derivatives as inhibitors of smooth muscle cell proliferation
12/12/1996WO1996039387A1 Diheterocyclic acrylonitriles as smooth muscle cell proliferation inhibitors
12/12/1996WO1996039385A1 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
12/12/1996WO1996039384A1 Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
12/12/1996WO1996039383A1 Substituted benzene-fused hetero- and carbocyclics as neurokinin antagonists
12/12/1996WO1996039382A1 Urea derivatives as 5-ht antagonists
12/12/1996WO1996039374A1 2,4-pentadienoic acid derivatives having retinoid-like biological activity
12/12/1996WO1996039372A2 Macrophage lipid chemoattractant
12/12/1996WO1996039367A1 Heterocyclic methyl free radicals as image enhancing agents
12/12/1996WO1996039224A1 Device for transdermal electrotransport delivery of fentanyl and sufentanil
12/12/1996WO1996039223A1 Device for transdermal electrotransport delivery of fentanyl and sufentanil
12/12/1996WO1996039222A1 Device for transdermal electrotransport delivery of fentanyl and sufentanil
12/12/1996WO1996039196A1 Gene transfer for treating a connective tissue of a mammalian host
12/12/1996WO1996039194A1 Novel cathepsin and methods and compositions for inhibition thereof
12/12/1996WO1996039192A1 Treatment of cholera
12/12/1996WO1996039191A1 Treatment of cholera
12/12/1996WO1996039190A1 Treatment of traveller's diarrhea
12/12/1996WO1996039189A1 Treatment of traveller's diarrhea
12/12/1996WO1996039158A1 Pineal gland specific gene-1
12/12/1996WO1996039156A2 Phosphate-binding polymers for oral administration
12/12/1996WO1996039155A1 Immunopotentiator
12/12/1996WO1996039154A1 Oligonucleotides having phosphorothioate linkages of high chiral purity
12/12/1996WO1996039153A2 Use of di-beta-d-glucopyranosylamine compounds for controlling inflammatory reactions, and method of synthesis
12/12/1996WO1996039152A1 Use of locally applied dna fragments
12/12/1996WO1996039151A1 Bisphosphonates prevent bone loss associated with immunosuppressive therapy
12/12/1996WO1996039150A1 Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
12/12/1996WO1996039149A1 Anhydrous alendronate monosodium salt formulations
12/12/1996WO1996039148A1 Methods and compositions for inhibiting cytomegalovirus replication
12/12/1996WO1996039147A2 Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases
12/12/1996WO1996039146A1 Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
12/12/1996WO1996039145A1 Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties
1 ... 6849 6850 6851 6852 6853 6854 6855 6856 6857 6858 6859 6860 6861 6862 6863 6864 6865 6866 6867 6868 6869 ... 7860